A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1).

Trial Profile

A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2015

At a glance

  • Drugs Tamibarotene (Primary)
  • Indications Acute promyelocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms STAR-1
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jul 2012 Company added in the association field as reported by EudraCT.
    • 13 Mar 2012 Planned end date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top